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ChairsMatthias Barton, MD, FAHA, is a Professor
of Cardiology at the University of Zurich in
Switzerland. He is a graduate of Hannover
Medical School, Germany, and received his
clinical training in internal medicine, cardiolo-http://dx.doi.org/10.1016/j.lfgy, and anaesthesiology at Hannover Medical
School and the University Hospitals of Basel,
Bern, and Zurich. He has a clinical interest in
preventive cardiology and from 1999 held a
SCORE Career Development Award from theSwiss National Science Foundation to study novel factors involved in
coronary artery disease. His research uses translational approaches to
investigate molecular mechanisms underlying coronary artery and kid-
ney disease. Dr. Barton has studied hormonal regulation of vascular risk
and endothelial mediators as disease modiﬁers for more than 20 years.
His current research relates to the identiﬁcation of molecular mecha-
nisms of vascular and renal disease, speciﬁcally those linked to child-
hood obesity, and applying functional genomics to identify novel
factors involved in atherogenesis. Dr. Barton is a Fellow of the American
Heart Association, a member of the International Advisory Board of the
International Conferences on Endothelin, and Guest Editor of the ET-12
proceedings Endothelin XII.Anthony P. Davenport, PhD, directs the
Human Receptor Research Group in the Clinical
Pharmacology Unit at University of Cambridge
focusing on understanding the role of G
protein-coupled receptors, and their transmit-
ters in the human cardiovascular system and
how these are altered with disease. The role of
endothelin in human pathophysiology, especial-
ly the development of atherosclerosis has been a
major research interest since the discovery ofthe peptide in 1988. He has published over 200 papers and reviews to
date with over 130 devoted to endothelin. These include quantifying
and imaging endothelin receptors in normal and diseased human
tissue with sub-type selective radioligands and antisera as well as
positron emission tomography to non-invasively image endothelin
receptors in vivo. Wider research interests are reﬂected through
membership and co-vice chair of the International Union of Pharma-
cology (IUPHAR) Committee on Receptor Nomenclature and Drugs.2012.07.014 Open access under CC BY-NC-ND license.Classiﬁcation which maintains the GPCR and ion channel database,
including latest parings of orphan receptors with their cognate li-
gands. Dr. Davenport is a member of the International Advisory
Board of the International Conferences on Endothelin.
Honorary ChairsPaul M. Vanhoutte, MD, PhD, FAHA, is a Chair
Professor in the Department of Pharmacology
and Pharmacy of the Li Ka Shing Faculty of
Medicine of the University of Hong Kong. He
obtained his MD degree at the University of
Gent, Belgium. He has been Professor of Phar-
macology at the University of Antwerp, the
Mayo Clinic, Rochester MN, and Baylor Col-
lege of Medicine, Houston TX. From 1992 to
2002, he was Director of Discovery Researchat Servier near Paris in France. Dr. Vanhoutte is Doctor honoris causa
of the Universities of Gent, Antwerp, Zurich, Montréal and Strasbourg,
of the RMIT University in Melbourne, Australia, and of the Gr. T. Popa
University in Iasi, Romania. Dr. Vanhoutte is a Highly Cited Researcher
(ISI) in three categories: Biology&Chemistry, Pharmacology, and Clinical
Medicine. Dr. Vanhoutte was the Chair of the Third International
Conference on Endothelin (ET-3) held at Housten in 1993 and Honorary
Chair of the Sixth International Conference on Endothelin (ET-6) held
in Montréal, Canada, in 1999, the Ninth International Conference on
Endothelin (ET-9) held in Park City, Utah, in 2005 and the Twelfth Interna-
tional Conference on Endothelin (ET-12) held in Cambridge, UK, in 2011.Masashi Yanagisawa, MD, PhD, is an Investi-
gator of the Howard Hughes Medical Institute
(HHMI) and a Professor of Molecular Genetics
at the University of Texas Southwestern Med-
ical Center at Dallas, where he holds the Pat-
rick E. Haggerty Distinguished Chair in Basic
Biomedical Science. Dr. Yanagisawa discov-
ered endothelins, the most potent vasocon-
strictors known. He identiﬁed their receptors
and processing enzymes and demonstratedtheir role in the development of neural crest-derived tissues. He also
discovered the orexins and their receptors, proteins that regulate
food intake and wakefulness. Promising therapeutic applications
have emerged from his extraordinary research. Dr. Yanagisawa is a
member of the National Academy of Sciences (NAS) of the United
States of America and member of the International Advisory Board of
456 Conference Faculty, Session Chthe International Conferences on Endothelin. He was honorary chair of
the Eleventh International Conference on Endothelin (ET-10) held in
Bergamo, Italy, in 2007, the Eleventh International Conference on
Endothelin ET-11) held in Montréal, Canada, in 2009, and the Twelfth
International Conference on Endothelin (ET-12) held in Cambridge,
UK, in 2011.
Local Organizing Committee and International Scientiﬁc Advisory
Board MembersKerstin Amann, MD, is a Professor and Head
of the Department of Nephropathology at the
Department of Pathology, University Erlangen-
Nürnberg, Germany. She studied medicine at
the University of Heidelberg and specialized in
pathology thereafter. In 1999 she moved to
Erlangen and focused on nephropathology.
Dr. Amann research interest relates to causes
and consequences of chronic kidney disease
(CKD) with particular emphasis on cardiovascu-lar disease in CKD where she and her group have demonstrated a patho-
genetic role for endothelin-1 in a large number of studies. Dr. Amann is a
member of the Board of theGerman Society of Nephrology and theGerman
Institute for High Blood Pressure and a member of the Local Organizing
Committee of the Twelfth International Conference on Endothelin (ET-12).Dennis L. Andress, MD, is the Senior Medical
Director for Renal Development with Abbott
Laboratories. Prior to his employment at Ab-
bott, he was Clinical Professor of Medicine
and Director of the Renal Dialysis Unit at
the Division of Nephrology, University of
Washington, Seattle, WA. Dr. Andress con-
tributed basic and clinical research discov-
eries related to complications of chronic
kidney disease and end-stage renal failurewith over 100 publications in peer-reviewed journals. His research
was supported by grants from the National Institutes of Health and
the Northwest Kidney Foundation. His current interest is in drug de-
velopment for diabetic nephropathy particularly as it relates to the
endothelin system and to the selective ETA receptor antagonist,
atrasentan. Dr. Andress is a member of the International Scientiﬁc
Advisory Committee of the Twelfth International Conference on
Endothelin (ET-12).Anna Bagnato, PhD, has been group leader in
the Laboratory A of Molecular Pathology at the
Regina Elena National Cancer Institute of
Rome, Italy, since 1998. She is the author of nu-
merous articles published on leading interna-
tional journals and book chapters and has
coordinated cancer research grants by public
and private agencies. Her research, deﬁning
many critical activities of the endothelin axis in
the development and the progression of cancer,in particular in ovarian carcinoma model, represents the translational
basis leading to the introduction of novel targeted therapies in the
ovarian cancer management. As a member of the Board of the Italian
Cancer Society, Dr. Bagnato plays an active role in promoting cancer re-
search and communicating science to the public. She is a member of
the Local Organizing Committee of the Twelfth International Conference
on Endothelin (ET-12).Ariela Benigni, PhD, is the Head of Depart-
ment of Molecular Medicine and the Scientiﬁc
Secretary of the Mario Negri Institute for
Pharmacological Research in Bergamo, Italy.
She completed a M.Sc. in biological sciences
airs, and Invited Speakersat the University of Milan and PhD at Maas-
tricht University. She was Associate Editor of
Kidney International and Journal of Nephrolo-
gy. She is currently involved in the Editorial
Board of Archives of Medical Science andInternational Journal of Artiﬁcial Organs. She is the author of more
than 200 scientiﬁc articles. Her research interest relates to mediators
of progressive renal injury with a major effort to ﬁnd therapies to in-
duce regression of renal lesions and kidney regeneration by various
drugs including endothelin antagonists. Cellular therapy with mesen-
chymal stem cells to prevent acute and chronic kidney injury as well
as gene therapy to overcome acute and chronic rejection of the graft
is additional research areas. She was Chair of the Tenth International
Conference on Endothelin (ET-10), held at Bergamo in 2007. Dr. Benigni
is a member of the International Advisory Board of the International
Conferences on Endothelin and is a member of the Local Organizing
Committee of the Twelfth International Conference on Endothelin (ET-
12).Subrata Chakrabarti, MBBS, PhD, FRCPC, is a
Professor and Chair of the Department of Pa-
thology at the University of Western Ontario,
London, Ontario, Canada. He also works as a
pathologist at the London Health Sciences
Center. His research focuses on complications
of diabetes and vascular biology. Dr. Chakrabarti
investigates mechanisms of chronic diabetic
complications and studies diabetic retinopathy,
nephropathy and diabetic heart disease and has
published extensively in this ﬁeld. He has along-standing interest in the role of endothelins in chronic diabetic com-
plications and other diseases. Dr. Charkabarti is a member of the
International Scientiﬁc Advisory Committee of the Twelfth International
Conference on Endothelin (ET-12).Martine Clozel, MD, is Senior Vice President
and Chief Scientiﬁc Ofﬁcer of Actelion Phar-
maceuticals. She is a pediatrician, specialized
in neonatal intensive care. She received her
MD degree and a Master of Pharmacology
from Nancy University, France, and further
training in physiology and pharmacology
from McGill University, Montréal, and the
University of California, San Francisco. She is
married and has 3 children. During 11 yearsat F. Hoffmann-La Roche Ltd, she initiated the research project on
endothelin and endothelin receptor antagonists which led to the
discovery and clinical development of bosentan (Tracleer®). In 1997
Dr. Clozel co-founded Actelion Pharmaceuticals Ltd, where she is
Senior Vice President and Chief Scientiﬁc Ofﬁcer (CSO). Her group
has published over 130 peer-reviewed papers in the ﬁelds of endo-
thelial biology, endothelin and endothelin receptor antagonists. In
1997 she was awarded the Hoffmann-La Roche Research Prize for
her achievements in endothelin research and was named Chevalier
de la Légion d'Honneur in 2008. Dr. Clozel is a member of the Interna-
tional Scientiﬁc Advisory Committee of the Twelfth International Con-
ference on Endothelin (ET-12).
n ChNeil Davie, PhD, is Global Clinical Director at
Bayer Healthcare, UK, and until 2011 was
Early Candidate Medical Director in Pﬁzer's
Specialty Care Business Unit responsible for
the clinical development of endothelin antago-
Conference Faculty, Sessionists. Dr. Davie's main role is the identiﬁca-
tion of novel therapeutic targets to answer
unmet medical needs in pulmonary vascular
disease through research partnerships and
business development. Before joining indus-try, Dr. Davie was Head of Cell and Molecular Biology and Assistant
Professor of Pediatric Cardiology at the University of Colorado Health
Sciences in Denver, USA. A pulmonary vascular biologist by training,
Dr. Davie has worked in the ﬁeld of pulmonary arterial hypertension
(PAH) and endothelin biology for over 13 years. Dr. Davie received his
bachelor's degree in Biomedical Science from the University of Leeds
and his Doctorate in Clinical Pharmacology from Imperial College
School of Medicine in London. His doctoral thesis was entitled “The
Role of Prostacyclin and Endothelin in Pulmonary Vascular Disease”.
Dr. Davie is a member of the International Scientiﬁc Advisory Commit-
tee of the Twelfth International Conference on Endothelin (ET-12).Michael R. Dashwood, PhD, obtained his
PhD in Physiology at the University of
London in 1986 having previously been at
the National Institute for Medical Research
in London where his original research was
investigating central sites of opioid induced
analgesia and cardiovascular control. For
the last 20 years his focus has shifted from
brainstem regions involved in central car-
diovascular control to the ‘local’ vascular ef-fects of endothelium-derived nitric oxide and endothelin. These
studies have generated a number of research papers, reviews and
book chapters describing the potential involvement of these fac-
tors in diseases including atherosclerotic vascular disease such as
critical limb ischemia and venous disease including vein graft fail-
ure. Dr. Dashwood is a member of the International Scientiﬁc Ad-
visory Committee of the Twelfth International Conference on
Endothelin (ET-12).Jo G. R. De Mey, PhD, is professor of Vascular
Pharmacology at the Cardiovascular Research
Institute Maastricht (CARIM) of Maastricht
University, the Netherlands. He was trained as
a zoologist (M.Sc.) and as a pharmacologist
(PhD) at the University of Antwerp. Before
joining Maastricht University he headed a
cardiovascular department in pharmaceuti-
cal industry focussing on therapeutic appli-
cations of natriuretic peptides. He is theauthor of more than 160 scientiﬁc articles covering early as-
pects of endothelium-dependent vascular reactivity, endothelial
dysfunction in hypertension, endothelium dependent arterial re-
modelling in experimental models of heart failure and diabetes
and, more recently, molecular pharmacology of ET-receptors and
endogenous functional antagonists of ET-receptor function such
as CGRP. He coordinates the cardiovascular research within the
Dutch public–private partnership Top Institute Pharma that ad-
dresses among others “metalloproteases and novel targets in endo-
thelial dysfunction”. Dr. De Mey is a member of the Local
Organizing Committee of the Twelfth International Conference on
Endothelin (ET-12).Noriaki Emoto, MD, PhD, is a Professor at the
Department of Internal Medicine at Kobe Uni-
versity Graduate School of Medicine and at
Kobe Pharmaceutical University. After his res-
idency as a cardiologist in Kobe University
457airs, and Invited SpeakersHospital, Japan, he conducted his graduate
studies and postdoctoral fellowship under
the supervision of Dr. Masashi Yanagisawa
in Dallas, Texas. He won the Louis N. Katz
Basic Science Research Prizes of the AmericanHeart Association in 1994 for the molecular identiﬁcation and charac-
terization of endothelin-converting enzymes. He moved back to Kobe,
where he leads his own laboratory as a physician-scientist. He is in
charge of the pulmonary hypertension program in Kobe University
Hospital. His major research interest is translational research on
endothelin. Dr. Emoto is a member of the International Scientiﬁc Ad-
visory Committee of the Twelfth International Conference on Endothelin
(ET-12), is the Co-Chair-elect of the Thirteenth International Conference
on Endothelin (ET-13) to be held in Tokyo, Japan, September 8–11,
2013, and has been designated Guest Editor of the Endothelin XIII
Proceedings to be published in Life Sciences.Adviye Ergul, MD, PhD, FAHA, is a Professor
of Physiology at the Georgia Health Sciences
University in Augusta, GA. She received her
PhD in Biochemistry and Molecular Biology
on a project related to endothelin-1 (ET-1)
structure and function. Since then she has
been interested in the physiology/pathophys-
iology of the ET system. She made the seminal
observation that plasma ET-1 concentrations
are much higher in African-American hyper-tensives which contributed signiﬁcantly to our understanding of the
ET system in salt-sensitive hypertension. She built a strong research
career on the roles of ET and its receptors in diabetes-associated com-
plications. She has over 85 scientiﬁc papers and her research has been
continuously supported by American Heart Association, American Diabe-
tes Association, National Institutes of Health and Veterans Administra-
tion. Dr. Ergul is a Fellow of the American Heart Association and a
member of the International Scientiﬁc Advisory Committee of the
Twelfth International Conference on Endothelin (ET-12).Hunter C. Gillies, MD, is a Senior Director in
clinical research at Gilead Sciences Inc. San
Francisco. He spent the past 13 years in the
pharmaceutical industry working on clin-
ical drug development, primarily focusing on
the cardiovascular effects of phosphodiester-
ase type 5 inhibitors (PDE5i) and endothelin
receptor antagonists (ERA). For the past eight
years has worked in the ﬁeld of pulmonary hy-
pertension including clinical research and tri-als in PAH and PH secondary to chronic lung disease. Currently
his research focus involves clinical trials involving new pharmaco-
logical targets and exploring the potential for pharmacological synergy
between PDE5i and ERAs. He has a number of peer reviewed publica-
tions on cardiovascular physiology and pharmacology, exercise
physiology and the development of PD5i for cardiopulmonary disor-
ders. Dr. Gillies is a member of the International Scientiﬁc Advisory
Committee of the Twelfth International Conference on Endothelin (ET-
12).
Chairs, and Invited SpeakersJoey P. Granger, PhD, FAHA, is the Billy S.
Guyton Distinguished Professor, Professor of
Physiology andMedicine, Director of the Center
for Excellence in Cardiovascular-Renal Re-
search, and Dean of the School of Graduate
458 Conference Faculty, SessionStudies in the Health Sciences at the University
of Mississippi Medical Center in Jackson, MS.
Dr. Grangerwas the 84th President of the Amer-
ican Physiological Society (APS, 2011–2012)
and currently serves on the AHA Council forHigh Blood Pressure Research leadership committee, and as an Associate
Editor for Hypertension. He has received several awards including the
American Physiological Society E.H. Starling Distinguished Lecture
Award and Bodil M. Schmidt-Nielsen Distinguished Mentor and
Scientist Award, American Heart Association Dahl Memorial Lecture,
American Society of Hypertension Young Scholar Award, the Inter-
national Society of Hypertension Demuth Research Award, Inter-
American Society of Hypertension Young Investigator Award,
the Regulatory and Integrative Physiology Young Investigator
Award of the APS Water and Electrolyte Section, the APS Harold
Lamport Award of the Cardiovascular Section, the Bowditch Lecture
of the American Physiological Society, and the AHA Established
Investigator Award. Granger's research has been continuously
funded by the National Institutes of Health since 1984. Dr. Granger
is a Fellow of the American Heart Association and a member of
the International Scientiﬁc Advisory Committee of the Twelfth
International Conference on Endothelin (ET-12).Anil Gulati, MD, PhD, FCP, is a Professor of
Pharmaceutical Sciences and Associate Dean
for Research at Midwestern University. He is
a United States Fulbright Scholar 2008–2009
and winner of International Ranbaxy Re-
search Award 2007. He obtained his MD in
1982 from King George's Medical College,
Lucknow, India and became Diplomate of the
American Board of Clinical Pharmacology
(1992). He was awarded a PhD in 1996 byErasmus University Rotterdam, The Netherlands. He is a Fellow of
the American College of Clinical Pharmacology. He has more than
265 peer reviewed publications and guided research of more than
70 graduate students and research fellows. Dr. Gulati has 21 patent
applications (six issued patents) and has founded three companies.
Medications developed by Dr. Gulati are undergoing clinical trials in
the United States and India. Dr. Gulati is a member of the Internation-
al Scientiﬁc Advisory Committee of the Twelfth International Confer-
ence on Endothelin (ET-12).David Langleben, MD, is a Professor in the
McGill University Faculty of Medicine and
Chief of Cardiology of the Jewish General
Hospital in Montréal, Canada. He founded
and directs the Center for Pulmonary Vascu-
lar Disease, the ﬁrst pulmonary hyperten-
sion clinic in Canada. His research interests
include lung vascular metabolism; behav-
iour and function of lung vascular cells;
vascular cell biology; epidemiology of pul-monary hypertension, and the development of new medications
for pulmonary hypertension. His work has been supported by the
Medical Research Council of Canada, The Canadian Institutes for
Health Research, the Fonds de la Recherche en Sante du Quebec,
the Heart and Stroke Foundations of Quebec and Canada, and the
Quebec Lung Association. Dr. Langleben is a member of theInternational Scientiﬁc Advisory Committee of the Twelfth Interna-
tional Conference on Endothelin (ET-12).Janet Maguire, PhD, is a Senior Research As-
sociate in the Clinical Pharmacology Unit,
University of Cambridge and a Fellow of
Queens' College, Cambridge. She is a member
of the BHF Receptor Research Group whose
focus is the pharmacology of established and
novel G-protein coupled receptors in the
human cardiovascular system with particular
expertise in the endothelin peptides and
their receptors. Dr. Maguire has co-authoredﬁfty two papers, six book chapters and sixteen reviews, and is Editor
and contributor of a volume, ‘Peptide Research Protocols: Endothelin’
for Humana Press. She is also involved in undergraduate and graduate
teaching in pharmacology, supervising pre-clinical medical and veter-
inary students and is a British Heart Foundation and Wellcome Trust/
Medical Research Council 4-year PhD programme Principal Investiga-
tor. Dr. Maguire is a member of the Local Organizing Committee of the
Twelfth International Conference on Endothelin (ET-12).Yasuo Matsumura, PhD, has been Professor of
Pharmacology at Osaka University of Pharma-
ceutical Sciences (Takatsuki, Osaka, Japan) since
2002. Professor Matsumura is a member of
council of the Japanese Pharmacological Society,
Japanese Society for Circulation Research, Nitric
Oxide Society of Japan, among others. He was a
member of the Editorial Staff (2007–2010) of
Folia Pharmacologica Japonica, an ofﬁcial journal
of The Japanese Pharmacological Society. HisPhD degreewas obtained (1987) at Osaka City UniversityMedical School.
His main areas of expertise, research and work include renal, heart, and
circulatory pharmacology, health food science, and vascular biology.
Dr. Matsumura is a member of the International Scientiﬁc Advisory
Committee of the Twelfth International Conference on Endothelin (ET-12).Takashi Miyauchi,MD, PhD, is a Professor at
the Cardiovascular Division at the Depart-
ment of Internal Medicine and the Tsukuba
Advanced Research Alliance (TARA) Center
at University of Tsukuba, Tsukuba, Japan. He
is a cardiologist who is also familiar with
pharmacology, molecular biology, biochem-
istry and physiology. He graduated from Uni-
versity of Tsukuba School of Medicine and
received his MD in 1983. Dr. Miyauchi gradu-
ated from University of Tsukuba GraduateSchool and got his PhD in 1990. The main theme of his research is
the investigation of the physiological and pathophysiological roles
of vasoactive peptides including endothelin in the cardiovascular
system. He published more than 200 papers, including work
on endothelin and cardiovascular diseases such as hypertension,
pulmonary hypertension, and heart failure in journals which include
Nature, Lancet, Circulation, and the American Journal of Physiology,
Dr. Miyauchi is a member of the International Scientiﬁc Advisory
Committee of the Twelfth International Conference on Endothelin
(ET-12) and is the Co-Chair-elect of the Thirteenth International Con-
ference on Endothelin (ET-13) to be held in Tokyo, Japan, September
8–11, 2013.
n ChJohn Pernow, MD, PhD, FESC, is Professor and
Head of the Cardiology Unit, Department of
Medicine, Karolinska Institutet, Stockholm,
Sweden. He is also senior consultant of cardi-
ology at the Department of Cardiology,
Conference Faculty, SessioKarolinska University Hospital. He is a mem-
ber of the scientiﬁc council of the Swedish
Heart and Lung Foundation. His research is fo-
cused on mechanisms behind and treatment
targeting endothelial dysfunction with specialemphasis on the role of endothelin in cardiovascular disease. John
Pernow has been active in endothelin research for 20 years and pub-
lished several papers regarding the pharmacology and pathophysiolog-
ical role of endothelin in cardiovascular disease and complications to
diabetes. An additional research area is protection against myocardial
ischemia and reperfusion injury in experimental and clinical studies.
Dr. Pernow is a Fellowof the European Society of Cardiology andmember
of the Local Organizing Committee of the Twelfth International Confer-
ence on Endothelin (ET-12).Giles Alexander Rae, PhD, graduated in Bio-
medicine from the Federal University of São
Paulo in 1976, obtained his M.Sc. and Ph.D.
degrees in Physiology from the University
of São Paulo in 1979 and 1985. He is current-
ly a Professor of Pharmacology of the Federal
University of Santa Catarina, Florianopolis,
Brazil, where he has been working since
1978, is a Research Fellow of the Brazilian
National Research Council and former presi-dent of the Brazilian Society of Pharmacology. He initiated studies
on endothelins in 1988 while receiving post-doctoral training at
the William Harvey Research Institute, in London, UK, and has
taken part in all International Conferences on Endothelin, except ET-
2. His main current research is directed towards investigating the
participation of endothelins in mechanisms of nociception and pru-
ritus. Dr. Rae is a member of the International Scientiﬁc Advisory
Committee of the Twelfth International Conference on Endothelin
(ET-12).Markus P. Schneider, MD, received his train-
ing in Internal Medicine and Nephrology at the
University of Erlangen- Nuremberg, Germany,
where he is currently Assistant Professor
and Attending Physician. As a research fellow
(2004–2007), he has worked in Professor David
Pollock's laboratory in Augusta, GA, studying
the role of the renal endothelin system in the
control of blood pressure. Upon return to
Germany, he was Co-Principal Investigator on aclinical researchproject fundedby theDeutsche Forschungsgemeinschaft,
to study the role of oxidative stress. He was previously Senior Lecturer in
Cardiovascular Medicine at the Institute of Cardiovascular and Medical
Sciences at the University of Glasgow, UK, and Honorary Consultant Phy-
sician. Particular clinical interests are the management of patients with
arterial hypertension and patients with chronic kidney disease. His cur-
rent research focuses on mechanisms of vascular dysfunction and
the control of renal haemodynamics. Dr. Schneider is a member of
the Local Organizing Committee of the Twelfth International Confer-
ence on Endothelin (ET-12).Sidney G. Shaw, PhD, is a Lecturer and Direc-
tor of the Vasoactive Peptide Research Group
in the Department of Clinical Research at the
University of Bern Switzerland. Before mov-
ing to Bern in 1984 to join the Department
459airs, and Invited Speakersof Hypertension he received his MA and PhD
from Oxford University. He subsequently
was tutor and lecturer in Biochemistry and
Neuropharmacology at Trinity College of the
University of Oxford. He is an editor andboard member of several scientiﬁc journals and has published exten-
sively on current research areas which include the pathophysiology of
cardiovascular disease, diabetes, liver ﬁbrosis and the neuropharma-
cology of alcohol addiction. Dr. Shaw is a member of the Local
Organizing Committee of the Twelfth International Conference on
Endothelin (ET-12).Pierre-Louis Tharaux, MD, PhD, is a Professor
at the Centre for Cardiovascular Research andDi-
rector of INSERM U970 at the Université Paris
Déscartes. Dr. Tharaux is nephrologist and cell
physiologist with an interest on mechanisms of
kidney injury in disease states. His research ad-
dresses issues that are relevant to disorders
such as hypertension, diabetic nephropathy,
sickle cell disease andvasculitis. He has beenpar-
ticularly interested in three systems that impactthese processes: (1) the endothelin (2) the renin-angiotensin, and
(3) the epidermal growth factor receptor systems. His studies have
taken advantage of genetic manipulation of these systems in mice to
identify new approaches to treatment and disease prevention. Thus,
his team is developing and reﬁning mouse models of human vascular
and kidney diseases. Dr. Tharaux is a member of the Local Organizing
Committee of the Twelfth International Conference on Endothelin (ET-
12).David J. Webb, MD, DSc, FRCP, FRSE,
FMedSci, is Professor of Therapeutics and
Clinical Pharmacology in the BHF Centre of
Research Excellence at the University of
Edinburgh, where he established its Centre
for Cardiovascular Science, and consultant
physician at the Royal Inﬁrmary of Edinburgh.
He is recognised internationally for his work
on endothelial function and arterial stiffness,
much of which focuses on the endothelin sys-tem, and on the investigation and effective treatment of patients
with complex hypertension and chronic kidney disease. His work
is mainly translational and he provides leadership to two new
UK clinical PhD training initiatives in translational medicine and
therapeutics (TMAT) based in Scotland, funded by the Wellcome
Trust and Medical Research Council. He is a Fellow of the Royal
Society of Edinburgh and UK Academy of Medical Sciences, and was
awarded the SKB Silver and Lilly Gold Medals from the British
Pharmacological Society for his research and for contributions
to pharmacology, respectively. Dr. Webb was Chair of the Seventh
International Conference on Endothelin (ET-7), held at Edinburgh in
2001. He is a member of the International Advisory Board of the
International Conferences on Endothelin and a member of the Local
Organizing Committee of the Twelfth International Conference on
Endothelin (ET-12).
Chairs, and Invited SpeakersET-12 Session Chairs and Invited SpeakersBrian D. Cain, PhD, is a Professor of Bio-
chemistry and Molecular Biology at the Uni-
versity of Florida at Gainesville. Dr. Cain
received a B.A. in Molecular, Cellular and De-
velopmental Biology from the University of
460 Conference Faculty, SessionColorado. He moved to the University of Illi-
nois, Urbana-Champaign for graduate stud-
ies earning a Ph.D. in Cell Biology in 1983.
His dissertation focused on phospholipid
metabolism and photosynthetic membranebiogenesis. In order to train in the application of modern molecular
biology approaches to membrane science, he pursued postdoctoral
studies at Stanford University. Dr. Cain joined the faculty of the Uni-
versity of Florida as an Assistant Professor in 1988 and was promot-
ed to Professor in 2000. His laboratory has received numerous
awards from the National Institutes of Health. Signiﬁcant career ac-
tivities include serving as Chairman of the NIH Physical Biochemis-
try Study Section, and participation on the NIH study sections for
the Specialized Centers for the Protein Structure Initiative and the
George M. O'Brien Kidney Centers. He also served a term on the
editorial board for The Journal of Biological Chemistry. Dr. Cain
chaired the 2011 Molecular and Cellular Bioenergetics Gordon
Research ConferenceJohn G. Cleland, MD, FRCP (Glasgow &
London), FESC, FACC, is Professor and Chair of
Cardiology at the University of Hull, Kingston-
upon-Hull, UK. He qualiﬁed in medicine in
1977 at the University of Glasgow. He was
appointed from 1986–1994 ﬁrst as a Senior
Registrar and subsequently as Senior Lecturer
in Cardiology jointly at St Mary's and the
Hammersmith Hospital, London. In 1994 he
was awarded a Senior Research Fellowship by
the British Heart Foundation to transfer to theMedical Research Council's Clinical Research Initiative in Heart Failure
in Glasgow. He was appointed Chair of Cardiology at the University of
Hull in 1999. His main interest is heart failure, extending from its epide-
miology, detection and prevention, to effective implementation of
existing treatments and planning of randomised trials of new (and
old) treatments. Particular interests include the interaction between
myocardial hibernation and treatment, ‘diastolic’ and vascular dysfunc-
tion, anti-thrombotic treatments, peri-partum cardiomyopathy, cardiac
resynchronisation, telemonitoring, implantable haemodynamic mon-
itoring, comorbidities including diabetes, anaemia, atrial ﬁbrilla-
tion and renal dysfunction and new interventions for acute heart
failure.Pedro d'Orléans-Juste, PhD, is a Professor of
Pharmacology (1990–Present) at Sherbrooke
University Medical School, Quebec, Canada. He
initiated his research endeavors on endothelins
in 1988, as a post-doctoral fellow (supervisor,
Sir John Vane, William Harvey Research Insti-
tute). Trained in cardiovascular pharmacology
during his graduate studies, Dr d'Orléans-
Juste was involved in the early report on the
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